1 link tagged with all of: clinical trial + genentech + biontech + immunotherapy
Click any tag below to further narrow down your results
Links
In a Phase 1 trial, personalized mRNA vaccines given after surgery triggered durable T cell responses in eight of 16 early-stage pancreatic cancer patients, with six responders alive six years later. Genentech and BioNTech have launched a Phase 2 trial while researchers study how killer and helper T cells sustain long-term immunity.
- Personalized mRNA vaccines given after pancreatic cancer surgery produced strong T-cell responses in 8 of 16 patients, and 6 of those responders are still alive six years later.
- Responders developed both killer and helper T cells, with helper T cells appearing key to sustaining the immune attack long-term.
- Genentech and BioNTech have moved forward with a larger Phase 2 trial based on these early results.
- A separate off-the-shelf KRAS-targeting vaccine triggered immune responses in about 85% of early trial participants, suggesting multiple vaccine strategies could help counter tumor evolution.